2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5604 GLP-1 receptor agonist associated with improve overall survival and clinical outcomes in patients with myelodysplastic syndromes and type 2 diabetes: A real-world analysis

Moath Albliwi, MD, Mohammed Aloqaily, MD2, Rahaf Yaghi, MD3, Ahmad Al-Alwan, MD4, Baha Faiyoumi, MD5, Alaa Salamat, MD6, Shady Hazzaa, MD7, Moath Alshudifat8, Mohammad Alqob9, Mohammed Yaman AL Matni, MD10, Moaath Mustafa Ali, MD, MPH11
1 Roswell Park Comprehensive Cancer Center / University at Buffalo, Buffalo, New York, United States
2 University of Maryland Medical Center, Baltimore, Maryland, United States
3 AlBalqa'a Applied University, Salt, Jordan
4 Roswell Park Comprehensive Cancer Center / University at Buffalo, Buffalo, New York, United States
5 University of Arizona, Tucson, Arizona, United States
6 HCA UK University, London, United Kingdom
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Ascension Saint Agnes Hospital, Baltimore, Maryland, United States
9 Ascension Saint Agnes Hospital, Baltimore, Maryland, United States
10 Saint Louis University, ST Louis, Missouri, United States
11 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Introduction
Patients with myelodysplastic syndromes (MDS) commonly present at advanced age, metabolic and cardiovascular comorbidities, and infectious complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential metabolic and cardiovascular benefits in the general population, but their effect and outcomes in patients with MDS and type 2 diabetes (DM2)remain poorly known. We investiaged the association of GLP-1 RA exposure with overall survival and many other clinical outcomes in this population group.

Methods
A retrospective cohort study was conducted using the TriNetX Global Network, comprising 180 healthcare institutions. Adults aged ≥18 years with MDS and DM2 were included. The exposure cohort includes patients with a GLP-1 RA medication record at least 3 months after the diagnosis of MDS and DM2. The active-comparator cohort comprised patients receiving metformin, insulin, sulfonylureas, thiazolidinediones, or dipeptidyl peptidase-4 inhibitors without GLP-1 RA exposure. Patients exposed to sodium-glucose cotransporter-2 inhibitors were excluded. Outcomes were assessed from day 1 after the index medication event through last available follow-up. The primary outcome was overall survival. Secondary outcomes included hospitalization, sepsis, major adverse cardiovascular events (MACE), a composite of blood-product or platelet transfusion and epoetin alfa use, and achievement of prespecified hemoglobin, platelet, and neutrophil thresholds. Propensity-score matching (PSM) incorporated demographic, clinical, MDS-related treatment, and laboratory characteristics. Risk ratios (RRs) with 95% confidence intervals (CIs), Kaplan–Meier analysis, Cox regression, and log-rank testing were used.

Results
Propensity-score matching yielded 135 patients per cohort. Mean age at index was 67.2±12.5 years in the GLP-1 RA cohort and 66.9±16.0 years in controls; 57.8% and 60.7%, respectively, were female. Rates of heart failure (29.6% vs 31.1%), stage 3 chronic kidney disease (25.2% vs 28.9%), and chemotherapy exposure (37.0% vs 37.8%) were similar. Median follow-up was 650 days with GLP-1 RA exposure and 432 days with comparator therapy.

After exclusion of patients with death documented before the outcome window, the survival analysis included 135 GLP-1 RA–exposed patients and 132 controls. Death occurred in 23 patients (17.0%) versus 45 patients (34.1%), respectively (RR, 0.500; 95% CI, 0.321–0.777; p=0.001). Kaplan–Meier survival curves differed significantly (log-rank p=0.002). Cox regression yielded an HR of 0.455 (95% CI, 0.274–0.754), although the proportional-hazards assumption was not met (p=0.012).

GLP-1 RA exposure was also associated with lower risks of the supportive hematologic composite (16.3% vs 33.3%; RR, 0.489; 95% CI, 0.312–0.767; p=0.001), sepsis (14.8% vs 28.9%; RR, 0.513; 95% CI, 0.316–0.832; p=0.005), hospitalization (34.8% vs 60.0%; RR, 0.580; 95% CI, 0.443–0.759; p<0.001), and MACE (11.1% vs 20.0%; RR, 0.556; 95% CI, 0.310–0.997; p=0.044). No significant differences were observed for hemoglobin ≥10 g/dL or platelet count ≥100×10³/µL. Neutrophil count ≥1.5×10³/µL was less frequently documented in the GLP-1 RA cohort (64.4% vs 77.0%; RR, 0.837; 95% CI, 0.716–0.977; p=0.023).

Conclusions
In this real-world PSM analysis of patients with MDS and type 2 diabetes, GLP-1 RA exposure was associated with lower mortality and lower risks of hospitalization, sepsis, supportive hematologic interventions, and MACE compared with alternative glucose-lowering therapies. However, the nonproportional hazards, residual baseline imbalance, small cohort size, and potential for unmeasured confounding limit causal interpretation. These findings are hypothesis-generating and warrant validation in larger studies with granular MDS risk, molecular tests, treatment, and longitudinal medication data.

 

Moath Albliwi, MD: No relevant conflicts of interest to declare.